Firebrick Pharma Ltd
FRE
Company Profile
Business description
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. The company is also engaged in the development of the follow-on Nasodine brand products.
Contact
440 Collins Street
Level 10
MelbourneVIC3000
AUST: +61 1300301874
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
stocks
Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27
Charts from the Australian Dividend Outlook show the sectors where they are abundant.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,276.60 | 19.90 | -0.21% |
| CAC 40 | 8,059.49 | 0.64 | -0.01% |
| DAX 40 | 24,632.42 | 35.29 | 0.14% |
| Dow JONES (US) | 46,475.28 | 126.50 | -0.27% |
| FTSE 100 | 9,515.73 | 33.14 | -0.35% |
| HKSE | 26,752.59 | 76.87 | -0.29% |
| NASDAQ | 23,015.44 | 27.94 | -0.12% |
| Nikkei 225 | 48,580.44 | 845.45 | 1.77% |
| NZX 50 Index | 13,570.86 | 2.38 | 0.02% |
| S&P 500 | 6,744.84 | 8.88 | -0.13% |
| S&P/ASX 200 | 8,969.80 | 25.20 | -0.28% |
| SSE Composite Index | 3,933.97 | 51.20 | 1.32% |